KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Assets (2016 - 2025)

Historic Assets for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $607.8 million.

  • Xenon Pharmaceuticals' Assets fell 2728.37% to $607.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.8 million, marking a year-over-year decrease of 2728.37%. This contributed to the annual value of $798.1 million for FY2024, which is 1727.4% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Assets stood at $607.8 million for Q3 2025, which was down 2728.37% from $674.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Assets' 5-year high stood at $964.8 million during Q4 2023, with a 5-year trough of $264.4 million in Q3 2021.
  • Moreover, its 5-year median value for Assets was $719.9 million (2023), whereas its average is $673.7 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Assets surged by 20235.17% in 2021 and then tumbled by 2728.37% in 2025.
  • Xenon Pharmaceuticals' Assets (Quarter) stood at $572.0 million in 2021, then surged by 31.84% to $754.1 million in 2022, then rose by 27.93% to $964.8 million in 2023, then decreased by 17.27% to $798.1 million in 2024, then dropped by 23.84% to $607.8 million in 2025.
  • Its Assets stands at $607.8 million for Q3 2025, versus $674.3 million for Q2 2025 and $743.3 million for Q1 2025.